Abstract
Tumor necrosis factor (TNF) blockers are highly effective in treating psoriasis and psoriatic arthritis. This article provides an update on the safety profile of TNF blockers to include new data regarding exposures during pregnancy, as well as serious infections. Currently, the published literature suggests that TNF inhibitors carry low risk to the fetus. New data show that immunization of neonates with live vaccines is not advisable until after 6 months of age if their mothers were administered TNF blockers during pregnancy. However, there is no evidence that mothers receiving TNF blockers should refrain from breastfeeding. In 2011 the US Food and Drug Administration modified its warnings regarding infection, because recent evidence suggests that TNF blockers may increase the risk of both Listeria and Histoplasma fungal infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
